000538 云南白药
交易中 07-22 10:24:39
资讯
新帖
简况
云南白药：2025年公司在泰国生产的首批牙膏正式下线
证券之星 · 07-17
云南白药：2025年公司在泰国生产的首批牙膏正式下线
股市必读：7月7日云南白药现497.2万元大宗交易
证券之星 · 07-08
股市必读：7月7日云南白药现497.2万元大宗交易
云南白药获得外观设计专利授权：“药品包装盒（气血康口服液）”
证券之星 · 07-03
云南白药获得外观设计专利授权：“药品包装盒（气血康口服液）”
科捷物流连续拿下云南白药双项目，打造 B2B+B2C 一体化仓配标杆
智通财经 · 06-30
科捷物流连续拿下云南白药双项目，打造 B2B+B2C 一体化仓配标杆
云南白药(000538.SZ)拟投资3.6亿元建设无锡药业经皮给药技术产业平台项目
智通财经 · 06-24
云南白药(000538.SZ)拟投资3.6亿元建设无锡药业经皮给药技术产业平台项目
云南白药：公司将继续坚持战略性投资并购方向，持续提升对并购标的的专业研判与筛选能力
证券日报网 · 06-04
云南白药：公司将继续坚持战略性投资并购方向，持续提升对并购标的的专业研判与筛选能力
云南白药(000538.SZ)：INB301注射液获美国FDA新药临床试验许可
智通财经 · 06-03
云南白药(000538.SZ)：INB301注射液获美国FDA新药临床试验许可
云南白药（000538）披露董事会审议通过向参股公司推荐董事候选人议案，5月21日股价下跌1.28%
证券之星 · 05-21
云南白药（000538）披露董事会审议通过向参股公司推荐董事候选人议案，5月21日股价下跌1.28%
云南白药(000538)3月31日股东户数16.93万户，较上期减少9.01%
证券之星 · 04-30
云南白药(000538)3月31日股东户数16.93万户，较上期减少9.01%
云南白药：公司没有您所提及的合作
证券之星 · 04-30
云南白药：公司没有您所提及的合作
云南白药(000538.SZ)发布一季度业绩，归母净利润20.37亿元，增长5.31%
智通财经 · 04-29
云南白药(000538.SZ)发布一季度业绩，归母净利润20.37亿元，增长5.31%
云南白药（000538）披露持股5％以上股东可交换债换股价格调整公告，4月28日股价上涨1.01%
证券之星 · 04-28
云南白药（000538）披露持股5％以上股东可交换债换股价格调整公告，4月28日股价上涨1.01%
云南白药（000538）披露2025年年度权益分派实施公告，4月23日股价下跌0.37%
证券之星 · 04-23
云南白药（000538）披露2025年年度权益分派实施公告，4月23日股价下跌0.37%
股市必读：云南白药（000538）4月21日披露最新机构调研信息
证券之星 · 04-22
股市必读：云南白药（000538）4月21日披露最新机构调研信息
云南白药：4月1日召开业绩说明会，中信建投证券、国盛证券等多家机构参与
证券之星 · 04-02
云南白药：4月1日召开业绩说明会，中信建投证券、国盛证券等多家机构参与
股市必读：云南白药年报 - 第四季度单季净利润同比下降10.96%
证券之星 · 04-02
股市必读：云南白药年报 - 第四季度单季净利润同比下降10.96%
云南白药最新公告：INB301注射液获准开展肿瘤恶病质临床试验
证券之星 · 04-01
云南白药最新公告：INB301注射液获准开展肿瘤恶病质临床试验
云南白药(000538.SZ)发布2025年度业绩，归母净利润51.53亿元，增长8.51%
智通财经 · 03-31
云南白药(000538.SZ)发布2025年度业绩，归母净利润51.53亿元，增长8.51%
云南白药（000538）披露股东部分股份质押公告，3月24日股价上涨1.0%
证券之星 · 03-24
云南白药（000538）披露股东部分股份质押公告，3月24日股价上涨1.0%
3月17日云南白药发生1笔大宗交易 成交金额454.53万元
证券之星 · 03-17
3月17日云南白药发生1笔大宗交易 成交金额454.53万元
加载更多
公司概况
公司名称：
云南白药集团股份有限公司
所属行业：
医药制造业
上市日期：
1993-12-15
主营业务：
云南白药集团股份有限公司的主营业务是药品、健康品、中药资源的研发、生产及销售。公司的主要产品是工业产品（自制）、批发零售。2025年，云南白药第16年上榜财富中文网发布的《财富中国500强排行榜》，位列第357位；入选美国《制药经理人》杂志《全球制药企业50强排行榜》，位列第33位。
发行价格：
3.38
{"stockData":{"symbol":"000538","market":"SZ","secType":"STK","nameCN":"云南白药","latestPrice":51.28,"timestamp":1784687079000,"preClose":51.2,"halted":0,"volume":6244810,"delay":0,"changeRate":0.0016,"floatShares":1773000000,"shares":1784000000,"eps":2.9459,"marketStatus":"交易中","change":0.08,"latestTime":"07-22 10:24:39","open":51.1,"high":51.68,"low":50.8,"amount":320000000,"amplitude":0.0172,"askPrice":51.28,"askSize":31,"bidPrice":51.27,"bidSize":8,"shortable":0,"etf":0,"ttmEps":2.9459,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1784691000000},"marketStatusCode":2,"adr":0,"adjPreClose":51.2,"symbolType":"stock","openAndCloseTimeList":[[1784683800000,1784691000000],[1784696400000,1784703600000]],"highLimit":56.32,"lowLimit":46.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1784262603,"isCdr":false,"pbRate":2.17,"roa":"--","peRate":17.407244,"roe":"4.96%","epsLYR":2.89,"committee":0.193548,"marketValue":91497000000,"turnoverRate":0.0035,"status":0,"floatMarketCap":90916000000},"requestUrl":"/m/hq/s/000538","defaultTab":"news","newsList":[{"id":"2652409296","title":"云南白药：2025年公司在泰国生产的首批牙膏正式下线","url":"https://stock-news.laohu8.com/highlight/detail?id=2652409296","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652409296?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:18","pubTimestamp":1784279887,"startTime":"0","endTime":"0","summary":"证券之星消息，云南白药07月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘：公司年度报告显示，2025年公司主营收入仍全部在国内实现，这太让人失望了。按照云南白药的品牌影响力，公司走出去很难吗？2025年公司在泰国生产的首批牙膏正式下线，实现境外生产零的突破；完成马来西亚、印尼等多国产品注册，构建药品+健康品双轮驱动的全球注册体系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700031603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1807302812.USD","BK0239","LU1960683339.HKD","BK0028","BK0196","000538","LU1993786604.SGD","BK0188","BK0175","BK0187","BK0012","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649934507","title":"股市必读：7月7日云南白药现497.2万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2649934507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649934507?lang=zh_cn&edition=full","pubTime":"2026-07-08 01:49","pubTimestamp":1783446550,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，云南白药报收于48.65元，下跌1.28%，换手率0.41%，成交量7.2万手，成交额3.5亿元。当日关注点交易信息汇总：7月7日云南白药主力资金净流出1317.82万元。交易信息汇总：7月7日云南白药发生497.2万元大宗交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800001025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0187","BK0196","000538","LU1960683339.HKD","LU1993786604.SGD","BK0028","BK0239","BK0164","BK0012","LU1807302812.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648804676","title":"云南白药获得外观设计专利授权：“药品包装盒（气血康口服液）”","url":"https://stock-news.laohu8.com/highlight/detail?id=2648804676","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648804676?lang=zh_cn&edition=full","pubTime":"2026-07-03 03:27","pubTimestamp":1783020443,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示云南白药新获得一项外观设计专利授权，专利名为“药品包装盒”，专利申请号为CN202530764607.6，授权日为2026年7月3日。今年以来云南白药新获得专利授权14个，较去年同期增加了16.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300004812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1993786604.SGD","BK0012","LU1807302812.USD","BK0164","BK0028","BK0187","BK0188","LU1960683339.HKD","BK0196","BK0239","000538","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647958209","title":"科捷物流连续拿下云南白药双项目，打造 B2B+B2C 一体化仓配标杆","url":"https://stock-news.laohu8.com/highlight/detail?id=2647958209","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647958209?lang=zh_cn&edition=full","pubTime":"2026-06-30 13:55","pubTimestamp":1782798915,"startTime":"0","endTime":"0","summary":"近期，科捷物流再传佳音，再度中标云南白药集团股份有限公司及旗下子公司物流运输服务项目，服务云南白药健康品类、药品类、食品保健品、中药材等产品的物流运输服务，负责部分线路的运输服务，该项目目前已完成上线，运营状况平稳。谈及本次合作，科捷物流相关负责人表示，连续中标云南白药两大项目，是公司全渠道一体化仓配服务能力的有力印证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1960683339.HKD","LU0417516902.SGD","BK1155","000538","LU1807302812.USD","BK0164","BK0196","BK0239","LU0348825331.USD","BK0188","LU1993786604.SGD","BK0012","BK0028","BK0187","BK0175","00861","BK1586"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645891421","title":"云南白药(000538.SZ)拟投资3.6亿元建设无锡药业经皮给药技术产业平台项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2645891421","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645891421?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:53","pubTimestamp":1782294820,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云南白药(000538.SZ)发布公告，公司董事会审议通过《关于建设无锡药业经皮给药技术产业平台项目的议案》，公司全资子公司云南白药集团无锡药业有限公司将建设无锡药业经皮给药技术产业平台项目，该项目投资总预算为3.6亿元，项目规划核心成熟产品保供、创新升级产品落地、新型剂型研发储备三大产品管线，全面覆盖伤科核心品类深耕、高端透皮制剂拓展、创新剂型孵化全维度需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云南白药(000538.SZ)拟投资3.6亿元建设无锡药业经皮给药技术产业平台项目","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1993786604.SGD","BK0012","LU1807302812.USD","BK0164","BK0028","BK0187","BK0188","LU1960683339.HKD","BK0196","BK0239","000538","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640733163","title":"云南白药：公司将继续坚持战略性投资并购方向，持续提升对并购标的的专业研判与筛选能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2640733163","media":"证券日报网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640733163?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:02","pubTimestamp":1780581720,"startTime":"0","endTime":"0","summary":"证券日报网6月4日讯，云南白药在接受调研者提问时表示，公司将继续坚持战略性投资并购方向，持续提升对并购标的的专业研判与筛选能力，重点遴选与云南白药品牌定位、产品矩阵、渠道网络及核心竞争优势高度协同的标的，集中优势资源推动战略性并购突破，切实补强业务发展动能。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-04/doc-iniahhrk0190338.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-04/doc-iniahhrk0190338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0012","BK0164","BK0028","BK0196","BK0188","LU1960683339.HKD","BK0239","BK0175","000538","LU1807302812.USD","LU1993786604.SGD","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640004908","title":"云南白药(000538.SZ)：INB301注射液获美国FDA新药临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2640004908","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640004908?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:57","pubTimestamp":1780480643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云南白药(000538.SZ)发布公告，公司于近日收到美国食品药品监督管理局(简称“美国FDA”)的通知，由公司申报的INB301注射液新药临床试验申请(简称“IND”)已获得美国FDA许可，同意开展临床试验，拟开发适应症为肿瘤恶病质。该药品为公司研发的首个治疗用生物创新药，拟用于治疗肿瘤恶病质。肿瘤恶病质是一种由恶性肿瘤引发的复杂代谢紊乱综合征，以持续性骨骼肌消耗为特征，常规营养支持难以逆转。截至目前，已获得中美两国临床试验许可，累计已投入研发费用约人民币5066.5万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK0012","LU1807302812.USD","BK0164","LABU","LU1993786604.SGD","BK0028","BK0187","BK0188","LU1960683339.HKD","BK0196","BK0239","000538","BK4585","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637016334","title":"云南白药（000538）披露董事会审议通过向参股公司推荐董事候选人议案，5月21日股价下跌1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637016334","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637016334?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:14","pubTimestamp":1779372858,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，云南白药报收于50.13元，较前一交易日下跌1.28%，最新总市值为894.45亿元。该股当日开盘50.86元，最高50.88元，最低50.12元，成交额达3.46亿元，换手率为0.39%。近日，云南白药集团股份有限公司披露《第十一届董事会2026年第四次会议决议公告》。会议审议通过《关于向参股公司推荐董事候选人的议案》，表决结果为12票同意、0票反对、0票弃权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1993786604.SGD","BK0175","LU1960683339.HKD","LU1807302812.USD","BK0196","000538","BK0188","BK0028","BK0239","BK0012","BK0164","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631168497","title":"云南白药(000538)3月31日股东户数16.93万户，较上期减少9.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631168497","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631168497?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:37","pubTimestamp":1777541827,"startTime":"0","endTime":"0","summary":"证券之星消息，近日云南白药披露，截至2026年3月31日公司股东户数为16.93万户，较12月31日减少1.68万户，减幅为9.01%。在中药行业个股中，云南白药股东户数高于行业平均水平，截至3月31日，中药行业平均股东户数为5.39万户。从股价来看，2025年12月31日至2026年3月31日，云南白药区间跌幅为3.35%，在此期间股东户数减少1.68万户，减幅为9.01%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000056740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","000538","BK0196","LU1960683339.HKD","BK0164","LU1807302812.USD","LU1993786604.SGD","BK0175","BK0187","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631685904","title":"云南白药：公司没有您所提及的合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2631685904","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631685904?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:18","pubTimestamp":1777537102,"startTime":"0","endTime":"0","summary":"证券之星消息，云南白药(000538)04月30日在投资者关系平台上答复投资者关心的问题。投资者提问：1. 药石科技在分子砌块、连续流工艺、ADC/TPD关键中间体等领域具备国内独一档的技术壁垒，也是很多创新药公司早期研发和CMC开发的重要合作伙伴。请问贵司在管线研发中，是否与药石科技有合作？未来是否有计划在早期化合物发现、工艺开发或商业化生产层面开展合作？云南白药回复：您好！公司没有您所提及的合作，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000053094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0175","LU1993786604.SGD","LU1807302812.USD","BK0012","BK0188","BK0028","BK0164","BK0239","LU1960683339.HKD","000538","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631549680","title":"云南白药(000538.SZ)发布一季度业绩，归母净利润20.37亿元，增长5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631549680","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631549680?lang=zh_cn&edition=full","pubTime":"2026-04-29 23:43","pubTimestamp":1777477383,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云南白药(000538.SZ)发布2026年第一季度报告，该公司营业收入为116.03亿元，同比增长7.02%。归属于上市公司股东的净利润为20.37亿元，同比增长5.31%。归属于上市公司股东的扣除非经常性损益的净利润为19.65亿元，同比增长4.12%。基本每股收益为1.14元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云南白药(000538.SZ)发布一季度业绩，归母净利润20.37亿元，增长5.31%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000538"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630377434","title":"云南白药（000538）披露持股5％以上股东可交换债换股价格调整公告，4月28日股价上涨1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630377434","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630377434?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:07","pubTimestamp":1777370846,"startTime":"0","endTime":"0","summary":"截至2026年4月28日收盘，云南白药报收于54.84元，较前一交易日上涨1.01%，最新总市值为978.49亿元。该股当日开盘54.3元，最高54.85元，最低54.2元，成交额达5.46亿元，换手率为0.57%。云南白药集团股份有限公司于2026年4月28日发布《关于持股5％以上股东非公开发行可交换公司债券换股价格调整的提示性公告》。公告显示，公司持股5%以上股东新华都实业集团股份有限公司通知，其2025年面向专业投资者非公开发行的可交换公司债券换股价格将进行调整。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1807302812.USD","BK0012","LU1960683339.HKD","LU1993786604.SGD","BK0164","BK0175","BK0028","BK0188","BK0196","BK0187","000538"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629858043","title":"云南白药（000538）披露2025年年度权益分派实施公告，4月23日股价下跌0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629858043","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629858043?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:32","pubTimestamp":1776954739,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘，云南白药报收于54.28元，较前一交易日下跌0.37%，最新总市值为968.5亿元。该股当日开盘54.46元，最高54.65元，最低54.24元，成交额达3.59亿元，换手率为0.37%。近日，云南白药集团股份有限公司披露《2025年年度权益分派实施公告》。公告显示，公司2025年年度权益分派方案已获2026年4月21日召开的公司2025年度股东会审议通过。股权登记日为2026年4月29日，除权除息日为2026年4月30日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300062925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0239","BK0012","LU1993786604.SGD","BK0164","BK0188","LU1960683339.HKD","BK0028","BK0175","000538","BK0196","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629054089","title":"股市必读：云南白药（000538）4月21日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2629054089","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629054089?lang=zh_cn&edition=full","pubTime":"2026-04-22 03:00","pubTimestamp":1776798034,"startTime":"0","endTime":"0","summary":"截至2026年4月21日收盘，云南白药报收于55.06元，上涨0.11%，换手率0.25%，成交量4.42万手，成交额2.43亿元。云白国际2025年实现营业收入11.08亿港元，同比增长46.79%。香港市场完成多项药品经营资质认证，泰国生产的首批牙膏正式下线，完成马来西亚、印尼等多国产品注册。问：INR101Ⅲ期临床数据最新进展?答：INR101诊断核药项目已完成32家研究中心中的29家启动，累计入组239例受试者。洛索洛芬钠凝胶贴膏项目已获得临床试验批件，同时开展工艺验证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200006578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","LU1807302812.USD","BK0012","BK0188","000538","BK0187","LU1993786604.SGD","BK0196","LU1960683339.HKD","BK0175","BK0239","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574949","title":"云南白药：4月1日召开业绩说明会，中信建投证券、国盛证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574949","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624574949?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:55","pubTimestamp":1775120115,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年4月1日云南白药发布公告称公司于2026年4月1日召开业绩说明会，中信建投证券、国盛证券、光大证券、兴业证券、开源证券、国金证券、国联民生证券、中金公司、东方证券、东吴证券、广发证券、中信证券、投资者、东北证券、天风证券、浙商证券、华创证券、华泰证券、华安证券、国泰海通证券参与。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200027858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1807302812.USD","BK0012","LU1960683339.HKD","LU1993786604.SGD","BK1564","BK0164","BK0175","BK1147","BK0028","BK0188","BK0052","BK0196","BK0187","000538","BK0276","002670","06066"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624543812","title":"股市必读：云南白药年报 - 第四季度单季净利润同比下降10.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624543812","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624543812?lang=zh_cn&edition=full","pubTime":"2026-04-02 00:55","pubTimestamp":1775062513,"startTime":"0","endTime":"0","summary":"来自股本股东变化：截至2026年3月31日，云南白药股东户数环比下降8.1%，户均持股数量维持在1.04万股。来自业绩披露要点：云南白药2025年实现归母净利润51.53亿元，同比增长8.51%，但第四季度归母净利润同比下降10.96%。股本股东变化股东户数变动近日云南白药披露，截至2026年3月31日公司股东户数为17.1万户，较12月31日减少1.51万户，减幅为8.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200000662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000538"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624459447","title":"云南白药最新公告：INB301注射液获准开展肿瘤恶病质临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2624459447","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624459447?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:09","pubTimestamp":1775038166,"startTime":"0","endTime":"0","summary":"云南白药(000538.SZ)公告称，公司近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，同意INB301注射液开展肿瘤恶病质的临床试验。该产品为公司研发的治疗用生物制品1类创新药，拟用于治疗由恶性肿瘤引发的复杂代谢紊乱综合征。截至目前，该产品已投入研发费用约4347.2万元。公司提示，药物研发存在周期长、投入大及结果不确定性等风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100034303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","LU1807302812.USD","BK0012","BK0028","LU1993786604.SGD","BK0187","BK0196","BK0164","BK0188","BK0239","000538","LU1960683339.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623558156","title":"云南白药(000538.SZ)发布2025年度业绩，归母净利润51.53亿元，增长8.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623558156","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623558156?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:30","pubTimestamp":1774960212,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云南白药(000538.SZ)发布2025年年度报告，该公司营业收入为411.87亿元，同比增长2.88%。归属于上市公司股东的净利润为51.53亿元，同比增长8.51%。归属于上市公司股东的扣除非经常性损益的净利润为48.65亿元，同比增长7.55%。基本每股收益为2.89元。此外，拟向全体股东每10股派发现金红利15.83元(含税)。报告期公司业务结构持续优化，工业收入160.16亿元，占营业收入比重38.89%，比重同比上升2.75个百分点，工业收入增速达10.7%。2023年至今，工业收入占营收比重实现连续增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云南白药(000538.SZ)发布2025年度业绩，归母净利润51.53亿元，增长8.51%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000538"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621954320","title":"云南白药（000538）披露股东部分股份质押公告，3月24日股价上涨1.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621954320","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621954320?lang=zh_cn&edition=full","pubTime":"2026-03-24 22:41","pubTimestamp":1774363277,"startTime":"0","endTime":"0","summary":"截至2026年3月24日收盘，云南白药报收于55.49元，较前一交易日上涨1.0%，最新总市值为990.09亿元。云南白药集团股份有限公司近日发布公告称，公司股东新华都实业集团股份有限公司将其持有的公司10,450,000股股份质押给中国建设银行股份有限公司福州五一支行，用于融资担保。本次质押占新华都所持股份比例的2.40%，占公司总股本的0.59%。本次质押后，新华都及其一致行动人累计质押公司股份98,170,000股，占其合计持股的21.83%，占公司总股本的5.50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400040295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0239","BK0187","LU1993786604.SGD","BK0164","BK0196","LU1960683339.HKD","BK0012","BK0188","BK0028","000538","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620479654","title":"3月17日云南白药发生1笔大宗交易 成交金额454.53万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620479654","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620479654?lang=zh_cn&edition=full","pubTime":"2026-03-17 16:58","pubTimestamp":1773737934,"startTime":"0","endTime":"0","summary":"证券之星消息，3月17日云南白药发生大宗交易，交易数据如下：大宗交易成交价格54.5元，相对当日收盘价折价4.54%，成交8.34万股，成交金额454.53万元，买方营业部为国海证券股份有限公司山东分公司，卖方营业部为华泰证券股份有限公司天津东丽开发区二纬路证券营业部。近三个月该股共发生2笔大宗交易，合计成交7411.0手，折价成交2笔。截至2026年3月17日收盘，云南白药报收于57.09元，上涨0.53%，换手率0.5%，成交量8.83万手，成交额5.04亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700028662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0239","LU1960683339.HKD","LU1993786604.SGD","BK0188","BK0187","BK0164","LU1807302812.USD","000538","BK0012","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784687080482,"stockEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.0572},{"period":"3month","weight":-0.0322},{"period":"6month","weight":-0.0693},{"period":"1year","weight":-0.0445},{"period":"ytd","weight":-0.0711}],"compareEarnings":[{"period":"1week","weight":-0.0259},{"period":"1month","weight":-0.0553},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0626},{"period":"1year","weight":0.0856},{"period":"ytd","weight":-0.0263}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南白药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"169274人(较上一季度减少9.01%)","perCapita":"10473股","listingDate":"1993-12-15","address":"云南省昆明市呈贡区云南白药街3686号","registeredCapital":"178426万元","survey":" 云南白药集团股份有限公司的主营业务是药品、健康品、中药资源的研发、生产及销售。公司的主要产品是工业产品（自制）、批发零售。2025年，云南白药第16年上榜财富中文网发布的《财富中国500强排行榜》，位列第357位；入选美国《制药经理人》杂志《全球制药企业50强排行榜》，位列第33位。","listedPrice":3.38},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云南白药(000538)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云南白药(000538)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云南白药,000538,云南白药股票,云南白药股票老虎,云南白药股票老虎国际,云南白药行情,云南白药股票行情,云南白药股价,云南白药股市,云南白药股票价格,云南白药股票交易,云南白药股票购买,云南白药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云南白药(000538)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云南白药(000538)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}